Meyka Pro banner
Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. Common Stock Fundamental Analysis (NASDAQ: ADVB)

ADVB●NASDAQ
HealthcareMedical - Diagnostics & Research
$2.22
$0.31(12.25%)
U.S. Market opens in NaNh NaNm

Advanced Biomed Inc. Common Stock Fundamental Analysis (NASDAQ: ADVB)

Advanced Biomed Inc. Common Stock (NASDAQ: ADVB) shows strong financial fundamentals with a PE ratio of -18.54, profit margin of 47.60%, and ROE of 57.51%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

ROE57.51%
PEG Ratio-0.09
Current Ratio8.09

Areas of Concern

Operating Margin-53.37%
We analyze ADVB's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 64.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
64.3/100

We analyze ADVB's fundamental strength across five key dimensions:

Efficiency Score

Excellent

ADVB demonstrates superior asset utilization.

ROA > 10%
47.08%

Valuation Score

Excellent

ADVB trades at attractive valuation levels.

PE < 25
-18.54
PEG Ratio < 2
-0.09

Growth Score

Weak

ADVB faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-14.29%

Financial Health Score

Excellent

ADVB maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
8.09

Profitability Score

Moderate

ADVB maintains healthy but balanced margins.

ROE > 15%
57.51%
Net Margin ≥ 15%
47.60%
Positive Free Cash Flow
No

Key Financial Metrics

Is ADVB Expensive or Cheap?

P/E Ratio

ADVB trades at -18.54 times earnings. This suggests potential undervaluation.

-18.54

PEG Ratio

When adjusting for growth, ADVB's PEG of -0.09 indicates potential undervaluation.

-0.09

Price to Book

The market values Advanced Biomed Inc. Common Stock at 0.33 times its book value. This may indicate undervaluation.

0.33

EV/EBITDA

Enterprise value stands at -0.56 times EBITDA. This is generally considered low.

-0.56

How Well Does ADVB Make Money?

Net Profit Margin

For every $100 in sales, Advanced Biomed Inc. Common Stock keeps $47.60 as profit after all expenses.

47.60%

Operating Margin

Core operations generate -53.37 in profit for every $100 in revenue, before interest and taxes.

-53.37%

ROE

Management delivers $57.51 in profit for every $100 of shareholder equity.

57.51%

ROA

Advanced Biomed Inc. Common Stock generates $47.08 in profit for every $100 in assets, demonstrating efficient asset deployment.

47.08%

Following the Money - Real Cash Generation

Operating Cash Flow

Advanced Biomed Inc. Common Stock generates limited operating cash flow of $-777.44K, signaling weaker underlying cash strength.

$-777.44K

Free Cash Flow

Advanced Biomed Inc. Common Stock generates weak or negative free cash flow of $-777.89K, restricting financial flexibility.

$-777.89K

FCF Per Share

Each share generates $-0.47 in free cash annually.

$-0.47

FCF Yield

ADVB converts -21.40% of its market value into free cash.

-21.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-18.54

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.33

vs 25 benchmark

P/S Ratio

Price to sales ratio

28.80

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

8.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.58

vs 25 benchmark

ROA

Return on assets percentage

0.47

vs 25 benchmark

ROCE

Return on capital employed

-0.60

vs 25 benchmark

How ADVB Stacks Against Its Sector Peers

MetricADVB ValueSector AveragePerformance
P/E Ratio-18.5430.85 Better (Cheaper)
ROE57.51%473.00% Weak
Net Margin4759.53%5192.00% Neutral
Debt/Equity0.000.12 Strong (Low Leverage)
Current Ratio8.095.76 Strong Liquidity
ROA47.08%-1414.00% (disorted) Strong

ADVB outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Advanced Biomed Inc. Common Stock's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

90.65%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

35.22%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ